RESEARCH USE PRODUCT: Logix Smart™ 2019-nCoV Kit
The Impact of CoDx™ and Its Technology
CHANGING THE FUTURE
Logix Smart™ 2019-nCoV Novel Coronavirus Detection Kit
The Logix Smart™ 2019-nCoV kit uses our patented CoPrimer™ technology to detect the presence of ribonucleic acid (RNA) of the novel strain of coronavirus in a real-time RT-PCR kit that targets conserved regions in the virus genome.
Current Features:
- Research Use Only qPCR kit with CoPrimer technology for rapid detection of the COVID-19 gene RdRp.
- Includes RNAseP Internal Positive Control.
- CoPrimer tests are open system and compatible with most qPCR equipment.
- The kit is currently under verification and validation studies for upper and lower respiratory tract and serum specimens for the determination of limit of detection, precision, and specificity. Specifications of performance are not yet available to the public. Regulatory discussions for clearance under emergency use authorization have begun within the FDA, European Union, and the WHO.
- Components are sold in kits of 100 and 250 reactions
- For Research Use Only. Not for use in diagnostic procedures.
Request a quote for the RUO Logix Smart 2019-nCoV Kit
Intended Use
The Logix Smart 2019-nCoV novel coronavirus kit is intended for molecular biology applications to aid in the detection of the strain of coronavirus first identified in Wuhan, China on December 31, 2019.
For Research Use Only. Not for use in diagnostic procedures.
This product is not available for sale in the U.S.

Co-Diagnostics is a molecular diagnostics company with a unique mathematical approach to DNA test design. Our products offer a unique value proposition, making the detection of infectious disease and genetic disorders far more affordable worldwide.
Co-Diagnostics, Inc.
2401 South Foothill Dr, Suite D
Salt Lake City, Utah 84109
United States
1 (801) 438-1036
© 2016-2020 Co-Diagnostics, Inc. • All Rights Reserved.
LATEST NEWS RELEASE
Co-Diagnostics, Inc. to Amend Q2 2020 Form 10-Q to Show $0.51 Net Income per Share
Salt Lake City, Utah – November 2, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that following the discovery of an incorrectly...
ARCHIVE

Co-Diagnostics is a molecular diagnostics company with a unique mathematical approach to DNA test design. Our products offer a unique value proposition, making the detection of infectious disease and genetic disorders far more affordable worldwide.
Co-Diagnostics, Inc.
2401 South Foothill Dr, Suite D
Salt Lake City, Utah 84109
United States
1 (801) 438-1036
COMPANY
© 2016-2020 Co-Diagnostics, Inc. • All Rights Reserved.